First Malaria Vaccine RTS, S: A Step toward the Eradication of Malaria

  • سال انتشار: 1403
  • محل انتشار: مجله آرشیو رازی، دوره: 79، شماره: 4
  • کد COI اختصاصی: JR_ARCHRAZI-79-4_001
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 115
دانلود فایل این مقاله

نویسندگان

Amit Bhattacharya

Department of Zoology Ramjas College University of Delhi Delhi India ۱۱۰۰۰۷

Neetu Bhattacharya

Department of Zoology Dyal Singh College University of Delhi

چکیده

Malaria is a mosquito-borne life-threatening illness caused by the parasites, Plasmodium. Around ۵۰% of the world’s population is at danger of this infectious disease. Antimalarial drug-Artemisinin, extracted from the plant Artemisia annua and has become a fundamental part of treatment regime for malaria across the world. The use of Artemisinin-based combination therapies (ACTs) against uncomplicated malaria has been endorsed by World Health Organization (WHO). As per the latest World malaria report (۲۰۲۲), around ۲۴۷ million malaria cases were reported in ۲۰۲۱ from ۸۴ malaria endemic nations (including the territory of French Guiana), a considerable upsurge from ۲۴۵ million reported in the year ۲۰۲۰. One of the foremost reasons for this increase was linked with disturbance to services for prevention, diagnosis, and treatment measures during the recent COVID-۱۹ pandemic. On ۶th of October ۲۰۲۱, the WHO suggested RTS,S vaccine, the first malaria vaccine, for its use against Plasmodium falciparum malaria in children residing in areas with moderate to high transmission. In July ۲۰۲۲, WHO granted prequalification support for the RTS,S vaccine. One million plus children living in African countries (mainly Ghana, Kenya and Malawi) have got at least one dose of this groundbreaking malaria vaccine through programmes coordinated by WHO and international and country-level partners. RTS,S is a significant initial footstep in the path to production of other highly protective vaccines/multi-stage vaccines that may become a part of the malaria eradication programs in near future. Several malariologists are working on early clinical development or trial phases of first-generation and next-generation malaria vaccines, such as R۲۱/Matrix-M, and malaria vaccine using mRNA technology.

کلیدواژه ها

Malaria, Plasmodium, Artemisinin, RTS, S/AS۰۱ vaccine

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.